TELESIS BIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.08 USD | +11.32% |
|
+18.26% | -43.19% |
| May. 09 | Earnings Flash (TBIO) TELESIS BIO Reports Q1 Revenue $3.4M | MT |
| May. 09 | Telesis Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
| Sales 2024 * | 26.8M | Sales 2025 * | 37M | Capitalization | 6.87M |
|---|---|---|---|---|---|
| Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 0.26 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.19 x |
| P/E ratio 2024 * |
-0.27
x | P/E ratio 2025 * |
-0.38
x | Employees | 133 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 62.32% |
More Fundamentals
* Assessed data
More news
Latest transcript on Telesis Bio, Inc.
More recommendations
More press releases
More news
| 1 day | +11.32% | ||
| 1 week | +18.26% | ||
| 1 month | -37.21% | ||
| 3 months | -59.42% | ||
| 6 months | -45.86% | ||
| Current year | -43.19% |
1 week
3.33
4.37
1 month
3.337.29
Current year
3.3315.46
1 year
3.3339.24
3 years
3.33462.60
5 years
3.33462.60
10 years
3.33462.60
| Managers | Title | Age | Since |
|---|---|---|---|
Daniel Gibson
FOU | Founder | 47 | 11-03-23 |
Eric Esser
CEO | Chief Executive Officer | 54 | 22-04-30 |
William Kullback
DFI | Director of Finance/CFO | 64 | 23-08-27 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jami Nachtsheim
BRD | Director/Board Member | 65 | 21-05-31 |
| Director/Board Member | 65 | 21-04-30 | |
Gregory Herrema
BRD | Director/Board Member | 58 | 23-10-17 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 4.08 | +11.32% | 68,085 |
| 24-05-30 | 3.665 | -0.92% | 12,745 |
| 24-05-29 | 3.699 | +3.70% | 11,025 |
| 24-05-28 | 3.567 | +3.39% | 35,026 |
| 24-05-24 | 3.45 | -2.54% | 22,132 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotes
Telesis Bio Inc. is a provider of ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) solutions. The Company provides automated multi-omic and synthetic biology solutions focused on providing applications to enable researchers to rapidly and reproducibly build or write high-quality synthetic DNA and messenger Ribonucleic Acid (mRNA) and short oligonucleotides that are ready to use in many downstream synthetic biology enabled markets. Its BioXp system consolidates, automates, and optimizes the entire synthesis, cloning and amplification workflow. Its on-market and its planned solutions include BioXp 3250 system, BioXp 9600 system, BioXp portal, BioXp De Novo kits, BioXp Select kits, BioXp Next Generation Sequencing kits, Benchtop reagents and Custom Gibson Short Oligo Ligation Assembly (SOLA) enzymatic DNA synthesis (EDS) solutions. BioXp Select kits offer customers the ability to use non-Telesis Bio DNA while using the BioXp system to perform synthetic biology workflow applications.
Calendar
2024-08-05
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
4.08
Average target price
-
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -43.19% | 6.87M | |
| +7.01% | 217B | |
| +11.01% | 190B | |
| +19.20% | 143B | |
| +30.79% | 111B | |
| +1.48% | 64.59B | |
| +13.95% | 52.36B | |
| -0.16% | 48.45B | |
| -6.20% | 38.03B | |
| +0.91% | 35.61B |
- Stock Market
- Equities
- TBIO Stock
